Healthcare
AstraZeneca and Oracle partner on AI-enabled clinical research in Abu Dhabi
AstraZeneca and Oracle will explore AI and real-world data to improve hypertension care and clinical-trial recruitment in Abu Dhabi with M42.
On 20 October 2026, AstraZeneca and Oracle announced a non-binding agreement to explore artificial intelligence and real-world data applications in clinical research and patient care. The collaboration combines AstraZeneca’s scientific and therapeutic expertise with Oracle’s health-data, cloud, AI, analytics and clinical-workflow capabilities. The first planned program will focus on hypertension in Abu Dhabi, in partnership with M42. The companies intend to investigate how AI can help clinical teams identify patients with uncontrolled hypertension, support guideline-directed treatment and recruit eligible patients into clinical trials. They also plan to examine whether evidence generated in research can be integrated into routine care. The collaboration may later cover oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology conditions, and rare diseases. Its significance lies in applying AI to practical clinical-trial and care-delivery bottlenecks, particularly delayed patient identification and difficult recruitment. The planned continuous-learning model could allow insights from routine treatment and clinical research to inform future study design, safety monitoring and patient management. The announcement describes the initiative as exploratory, so the results and operational impact remain to be demonstrated.
Original source: Oracle via PR Newswire